Archives

NKOTB: New and Emerging Roles for GLP-1-Based Medications -RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

 

* The information below is current as of the time of the presentation in 12/2025. This is a very active and rapidly-changing area of research so the information may have changed by the time the audience member watches this presentation in the future.

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • List recent FDA-approved indications for GLP-1-based medications
  • Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease
  • Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications

Release and Expiration Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-25-065-H01-P

Session Code

25RW65-GLP35

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-065-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Khanh Dang, PharmD, CDCES, FNAP
Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Dang has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

1. Which of the following GLP-1-based medication has an FDA indication for reducing risk sustained eGFR decline, end-stage kidney disease and CV death in adults with type 2 diabetes mellitus and CKD?
A. dulaglutide
B. semaglutide
C. tirzepatide

*

2. Which of the following GLP-1-based medication has an FDA indication for obstructive sleep apnea (OSA)?
A. dulaglutide
B. semaglutide
C. tirzepatide

*

3. Which of the following mechanisms contributes to the cardiovascular risk reduction observed with GLP-1-based medications?
A. Direct blockade of angiotensin II receptors and weight loss
B. Improved endothelial function, decreased blood pressure, and weight loss
C. Increasing sympathetic nervous system activity

*

4. In the FLOW study, which supported semaglutide’s recent FDA label approval for kidney risk reduction, the primary composite endpoint (kidney failure, ≥50% sustained eGFR reduction, or kidney/cardiovascular death) was reduced by ____ compared to placebo.
A. ~10%
B. ~25%
C. ~50%

*

5. Which patient population was enrolled in the SURMOUNT-OSA study?
A. Adults with obstructive sleep apnea and normal body weight
B. Adults with BMI of 30 and higher and obstructive sleep apnea, with or without positive airway pressure therapy
C. Adults with central sleep apnea due to neurologic disease, receiving with positive airway pressure therapy

*

6. Which of the following is a proposed mechanism of how GLP-1-based medications can lead to both renal protection and improvement in metabolic-dysfunction steatohepatitis (MASH)?
A. Decreased inflammation
B. Increased insulin resistance
C. Increased blood pressure

Video

Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

Recognize diverse instances of off-label drug use in women's health, spanning preconception to menopause
Discuss risks and advantages associated with off-label drug utilization during

various reproductive stages
Identify the pharmacist's role in advocating for safe and informed off-label drug use for women’s health

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-040-H01-P

Session Code

23RW40-JXT85

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-040-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Kelsey Giara, PharmD
Freelance Medical Writer
Pelham, NH

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Kelsey Giara has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Pharmacist Post-test

Learning Objectives
After completing this continuing education activity, pharmacists will be able to
• RECOGNIZE diverse instances of off-label drug use in women's health, spanning pre-conception to menopause
• DISCUSS risks and advantages associated with off-label drug utilization during various reproductive stages
• IDENTIFY the pharmacist's role in advocating for safe and informed off-label drug use for women’s health

1. Which of the following can be treated through off-label use of metformin?
A. Hirsutism of PCOS
B. PCOS with BMI ≥ 25 kg/m2
C. Endometriosis

2. Which of the following medications is used off-label to induce ovulation in women experiencing infertility and trying to conceive?
A. Letrozole
B. Clomiphene citrate
C. Cetrorelix

3. Which of the following drugs is used off-label to treat menopausal hot flashes?
A. Clonidine
B. Paroxetine
C. Fezolinetant

4. Which of the following is TRUE about off-label medication use during pregnancy?
A. All drugs have sufficient efficacy and safety data to support their use during pregnancy
B. Providers should use the letter-based FDA rating system to aid in shared clinical decision-making
C. About three-quarters of pregnant women use medications for off-label uses during pregnancy

5. A patient comes to your pharmacy experiencing frequent hot flashes. She states that a friend suggested she try taking black cohosh. She takes lisinopril for hypertension and metformin for prediabetes, and she is otherwise healthy. Which of the following is the BEST response?
A. Black cohosh will interact with your blood pressure medication, so you should not take it. Ask your doctor about clonidine instead.
B. Black cohosh shows some benefit, but clinical trials are inconsistent and available data is insufficient. You can try taking 20 mg daily for a few weeks to see if your symptoms improve.
C. Black cohosh shows no benefit whatsoever for VMS of menopause. Ask your doctor about letrozole instead.

6. Which of the following is TRUE about Pregnancy Exposure Registries?
A. They steal data about women’s babies and sell it on the black market
B. They are FDA-sponsored registries that collect health information
C. Pregnant women volunteer to share their experiences with off-label drug use

Handouts

Download

VIDEO